PATENT CLAIM ANALYSIS

Application Number: 16008744
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["424", "172100"]

Abstract:
The invention relates to antibodies that bind to VEGFR-2. The antibodies are used for treating neoplastic diseases, hyperproliferative disorders, and angiogenic disorders and can be used alone or in combination with other agents.

Claim (Index 14):
The isolated polynucleotide of  claim 1 , wherein the polynucleotide encodes an antibody or fragment thereof comprising a light chain variable domain, wherein the light chain variable domain sequence is selected from the group consisting of SEQ ID NO:32 and a sequence that is at least 95% identical to SEQ ID NO:32.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 94.0
- Lexical Diversity: 1.27586
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15111102', '15517778', '11414742', '11342249', '11583994']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7475337835940994
- 35 USC 102 Novelty (BERT): 0.516485374064697
- Combined Prediction Score: 0.7244289426411592
- Mean Citation Score: 299.62283
- Max Citation Score: 312.7636
- Similarity Product: 218.9236106060505

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test